David M. Marks
Impact in
- Biological Psychiatry top 5%
- Tryptophan and brain disorders
- Behavioral Neuroscience top 5%
- Stress Responses and Cortisol
Papers in
- Pharmacology 16
- Treatment of Major Depression 9
- Musculoskeletal pain and rehabilitation 7
-
- Fibromyalgia and Chronic Fatigue Syndrome Research 8
- Schizophrenia research and treatment 2
- Co-authors
- Ashwin A. Patkar (22 shared papers)Chi‐Un Pae (20 shared papers)Prakash S. Masand (18 shared papers)Bharath Rathakrishnan (1 shared paper)Katherine A. Lin (1 shared paper)Jeffrey R. Petrella (1 shared paper)P. Murali Doraiswamy (1 shared paper)Kingshuk Roy Choudhury (1 shared paper)
- Journals
- Clinical Neuropharmacology (2 papers)Biomedicine & Pharmacotherapy (2 papers)Expert Opinion on Drug Safety (1 paper)Contemporary Clinical Trials (1 paper)Current Treatment Options in Neurology (1 paper)
- Partner nations
- United StatesSouth KoreaBelgium
In The Last Decade
David M. Marks
29 papers receiving 914 citations
Peers
Comparison fields: 5 of 112
- Biological Psychiatry 126
- Behavioral Neuroscience 131
- Psychiatry and Mental health 345
- Pharmacology 220
- Neurology 80
Countries citing papers authored by David M. Marks
This map shows the geographic impact of David M. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Marks more than expected).
Fields of papers citing papers by David M. Marks
This network shows the impact of papers produced by David M. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Marks. The network helps show where David M. Marks may publish in the future.
Co-authors
The 25 scholars most cited alongside David M. Marks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 275 | |
| 2 | 2008 | 91 | |
| 3 | 2008 | 60 | |
| 4 | 2008 | 55 | |
| 5 | 2009 | 50 | |
| 6 | 2007 | 47 | |
| 7 | 2009 | 46 | |
| 8 | 2008 | 45 | |
| 9 | 2008 | 44 | |
| 10 | 2009 | 35 | |
| 11 | 2008 | 28 | |
| 12 | 2008 | 20 | |
| 13 | 2008 | 18 | |
| 14 | Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. | 2009 | 15 |
| 15 | 2009 | 15 | |
| 16 | 2011 | 14 | |
| 17 | 2008 | 13 | |
| 18 | 2009 | 11 | |
| 19 | 2009 | 11 | |
| 20 | 2009 | 11 |
About David M. Marks
David M. Marks is a scholar working on Pharmacology, Psychiatry and Mental health, Physiology, Developmental Neuroscience and General Health Professions, having authored 29 papers that have together received 953 indexed citations. Recurring topics across this work include Treatment of Major Depression (9 papers), Fibromyalgia and Chronic Fatigue Syndrome Research (8 papers), Musculoskeletal pain and rehabilitation (7 papers), Anesthesia and Neurotoxicity Research (3 papers), Health, psychology, and well-being (2 papers), Intensive Care Unit Cognitive Disorders (2 papers), Tryptophan and brain disorders (2 papers) and Schizophrenia research and treatment (2 papers). The work is most often cited by research in Biological Psychiatry (126 citations), Behavioral Neuroscience (131 citations), Psychiatry and Mental health (345 citations), Pharmacology (220 citations) and Neurology (80 citations). David M. Marks has collaborated with scholars based in United States, South Korea and Belgium. Frequent co-authors include Ashwin A. Patkar, Chi‐Un Pae, Prakash S. Masand, Bharath Rathakrishnan, Katherine A. Lin, Jeffrey R. Petrella, P. Murali Doraiswamy, Kingshuk Roy Choudhury, Alessandro Serretti and Patrick Luyten. Their work appears in journals such as Clinical Neuropharmacology, Biomedicine & Pharmacotherapy, Expert Opinion on Drug Safety, Contemporary Clinical Trials and Current Treatment Options in Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.